First-line treatments for metastatic clear cell renal cell carcinoma (ccRCC) combine PD-1 immune checkpoint inhibition (ICI) with CTLA-4 ICI or angiogenesis targeted therapy (TT). Upon progression, common options include cabozantinib or lenvatinib + everolimus, although these regimens have never been directly compared. We hypothesized that lenvatinib + everolimus will improve progression-free survival (PFS) compared to cabozantinib after progression on PD-1…
A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)
Annals of Oncology | | A.W. Hahn, J. Chahoud, W.P. Skelton, Y. Yuan, A.J. Zurita, C. Kovitz, O. Alhalabi, M.T. Campbell, E. Jonasch, J. Lin, M. Desai, M.J.M.N. Santos, H. Hwang, P.G. Corn, P. Msaouel, N.M. Tannir
Topics: colorectal-cancer, kidney-cancer, cervical-cancer, immunotherapy, targeted-therapy, clinical-trials